Defective platelet aggregation to the calcium ionophore A23187 in a patient with a lifelong bleeding disorder

SJ MACHIN, JP KEENAN,* BA McVERRY*

From the Department of Haematology, The Middlesex Hospital Medical School, London W1 and the
*Department of Haematology, Liverpool University

SUMMARY  A patient with a lifelong bleeding disorder is presented with a prolonged bleeding time and abnormal aggregation and secretion responses to arachidonic acid, thromboxane A₂, PAF-acether and the divalent calcium ionophore A23187. Platelet ρ and dense granule contents and morphology appear normal. The proposed defect is due to an abnormality of a platelet intracellular calcium dependent process.

When platelets are activated, arachidonate is enzymatically released from platelet membrane phospholipids and subsequently converted via cyclo-oxygenase and thromboxane synthetase into the cyclic endoperoxides, PGG₂ and PGH₂ and to thromboxane A₉ (TXA₉). These compounds and especially TXA₉ are potent inducers of platelet aggregation and granule secretion. It has been suggested that TXA₉ may act as a calcium ionophore, releasing stored calcium from the dense tubular system and thus raising the level of free cytoplasmic calcium.

Mobilisation of intracellular calcium is involved in the regulation of several platelet functions and secretory processes, suggesting a controlling trigger role for intracellular calcium flux and free cytoplasmic calcium in the platelet activation process. Recently, a few patients have been described with a lifelong bleeding tendency in whom arachidonate metabolism including TXA₉ formation was normal but whose platelets were unresponsive to TXA₉ showing defective aggregation and granule release. Also a similar acquired defect has been reported in one patient with chronic myeloid leukaemia.

We present here a patient with a lifelong bleeding tendency who has abnormal aggregation and secretion responses suggesting a defect in either the mobilisation of intracellular calcium, or a response to free cytoplasmic calcium.

Patient and methods

CASE REPORT

A 57-year-old Caucasian housewife presented with a lifelong bleeding disorder. As a child, she had frequent epistaxis lasting up to 24 h at a time until 16 years old. Since then, she has had widespread spontaneous non-traumatic purpura but not excessive menstrual loss or serious bleeding episodes. She had no operations in the past and had previously been told to avoid all drugs. She did not imbibe alcohol. A family history was relevant in that two brothers died in childhood from uncontrollable haemorrhage after minor trauma in one case and abdominal surgery in the other. Two other sisters and a brother were untroubled by bleeding, one sister having had an uncomplicated appendicectomy. Her parents had lived into old age without any bleeding problems. Physical examination was normal apart from some purpuric lesions on the lower limbs. Initial studies showed a normal blood and platelet count, normal renal and liver biochemical profiles and normal concentrations of immunoglobulin.

Methods

As anticoagulant, one volume of 3·13% sodium citrate was used for nine volumes of blood. Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were prepared by centrifugation at 164 g for 10 min and 1465 g for 15 min respectively at 22°C. Bleeding times were performed by the template method using a Simplate-II from General
Defective platelet aggregation to the calcium ionophore A23187

Diagnosics. Platelet counts were performed using a Technicon Autocounter (Technicon Instruments). Coagulation parameters were performed by standard techniques.10

The patient had been examined on four occasions. On each occasion a healthy control subject, who had ingested no drugs for the previous 14 days, and a control subject who had ingested 900 mg of acetylsalicylic acid 12 h previously, were studied simultaneously.

Platelet-aggregation studies were performed with an Aggregometer dual-channel aggregometer at 37°C. Aliquots of PRP (500 µl) or washed platelet suspensions, with a final platelet count of 200–300 × 10^9/l were placed in a cuvette in the aggregometer and aggregation induced with a final concentration of 2–16 µmol/l adenosine-5’-diphosphate (ADP Sigma), 1–2 µmol/l arachidonic acid, sodium salt (Sigma), 1–0–1-5 mg/ml ristocetin (H Lundbeck, Copenhagen), 1–6 µg/ml collagen (Hormon Chemie, Munich), 0-5–2.5 mg/ml endoperoxide analogue U-44069 (kindly supplied by Dr GL Bundy, Upjohn, Kalamazoo, Michigan), 1–12-5 µmol/l ionophore A23187 (Calbiochem, La Jolla, California), 0–5–2.5 mg/ml PAF-acether (1-0–alkyl-2-acetyl-glyceryl-3-phosphorylcholine; Calbiochem, La Jolla, California) and 0-2–1-0 U/ml human thrombin (Blood Products Laboratory, Elstree, UK). Platelets were washed by an albumin gradient separation technique11 and resuspended in a calcium-free TRIS HCl buffered saline, pH 7-4.

Platelet electron microscopy, thromboxane B2 (TXB2) in serum and after release from platelets in response to various stimuli, malondialdehyde (MDA) formation after stimulation with 1 mmol/l N-ethylmaleimide (NEM), plasma 6-keto prostaglandin F1α and cyclic AMP levels in unstimulated PRP were assayed as previously described.12 Platelet lysate was examined for antigenic material related to platelet PF4 and factor VIII:Rag.13

The concentrations of the platelet nucleotides ATP and ADP and their release after platelet stimulation by various agonists were determined by the firefly-luminescence method as described previously.14 The PRP was corrected to a final platelet count of 300 × 10^9/l in all experiments involving platelet nucleotide determinations.

Results

The patient consistently had a prolonged bleeding time of >30 minutes with a platelet count ranging between 223–357 × 10^9/l. All the coagulation parameters including the thrombin time, prothrombin time, activated partial thromboplastin time, factors VIII:C, factor VIII:Rag and factor VIII:RiCoF gave normal results.

Aggregation tracings of the patients and normal control PRP in response to ADP, collagen, arachidonic acid, U44069, A23187 and PAF-acether are shown in Fig. 1. Aggregation was reversible with ADP (2–16 µmol/l), with the endoperoxide analogue U44069 (0.5–2.5 µg/ml) and with PAF-acether (0.05–0.5 µg/ml). Aggregation was delayed and reduced in response to arachidonic acid (0.5–2 mmol/l) collagen (1–6 µg/ml) and the calcium ionophore A23187 (1–12.5 µmol/l). Ristocetin (1–0–1.5 mg/ml) gave normal aggregation. Upon stimulation the patient’s platelets underwent a normal shape change to all the above agonists. Aggregation of washed platelets with thrombin (0-2–1-0 U/ml) was normal. Normal washed platelets do not form platelet aggregates in response to A23187 (1–2 µmol/l),13 but on the addition of 0.5 mmol/l exogenous calcium both control and the patient’s washed platelets produced similar aggregation responses.

In a transfer experiment, PRP from the patient and control were stirred in the aggregometer for 30 s after the addition of 1 mmol/l arachidonic acid. After rapid centrifugation for 30 s, 100 µl of each platelet poor supernatant was added to 400 µl of PRP from the patient or from a normal subject who had ingested 900 mg of aspirin 12 hours previously. These mixtures were stirred in the aggregometer and aggregation recorded (Fig. 2). Supernatant from the control induced full aggregation of the aspirin-treated PRP but none with the patient’s PRP. Similarly supernatant from the patient induced full aggregation of the aspirin-treated PRP but none with the patient’s own PRP.

Malondialdehyde formation, serum thromboxane B2 (TXB2) production and the generation of thromboxane B2 from PRP after stimulation with 2 µg/ml collagen and 1 mmol/l arachidonic acid, and plasma 6-keto prostaglandin F1α levels are shown from the patient and a normal subject who had ingested 900 mg of aspirin 12 hours previously in Table 1. The patient’s total platelet ATP and ADP contents and ATP/ADP ratio were within our normal range as previously reported.14 The percentage release of platelet ATP and ADP after stimulation with A23187, collagen and PAF-acether are also shown for the patient and a normal control (Table 2).

The total ATP and ADP contents and ATP/ADP ratio from washed platelets of the patient and a normal subject and the percentage release of platelet ATP and ADP after stimulation with A23187 are shown in Table 3.

By light and electron microscopy the patient’s platelets showed normal morphology and granule
Intra platelet PF4 and factor VIII:Rag content appear to be normal. The concentration of cyclic AMP in the patient's unstimulated PRP was 23·71 pmol/10^8 platelets (normal range 14·7–33·8 pmol/10^8 platelets).

**Fig. 1** Aggregation tracings of the patient (P) and normal control (N) to various agonists.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patient</th>
<th>ASA:Control</th>
<th>Normal range</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA after NEM stimulation (nmol/10^8 platelets)</td>
<td>3·2</td>
<td>&lt; 0·2</td>
<td>1·1–3·94</td>
</tr>
<tr>
<td>Serum TXB_2 (ng/ml)</td>
<td>409</td>
<td>&lt; 10</td>
<td>200–900</td>
</tr>
<tr>
<td>TXB_2 generation* 2 μg/ml Colagen (ng/ml)</td>
<td>272</td>
<td>&lt; 10</td>
<td>163–297</td>
</tr>
<tr>
<td>TXB_2 generation* 1 mmol/1 arachidonic acid (ng/ml)</td>
<td>303</td>
<td>&lt; 10</td>
<td>251–394</td>
</tr>
<tr>
<td>Plasma 6-keto PGFα (pg/ml)</td>
<td>24</td>
<td>&lt; 10</td>
<td>0–80</td>
</tr>
</tbody>
</table>

*The platelet counts of PRP were all corrected to 300 × 10^9/l and the stimulus applied for 4 min in the aggregometer.

**Conclusions**

This patient's platelets were normal in number and morphology and contained normal α and dense granule contents. However, they showed markedly...
Defective platelet aggregation with A23187 in agonists. Each value is the mean of two determinations.

<table>
<thead>
<tr>
<th>Agonists (final concentration)</th>
<th>Patient</th>
<th>Control subject</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ATP</td>
<td>ADP</td>
</tr>
<tr>
<td>2-5 μmol/l A32187</td>
<td>3-2</td>
<td>5-9</td>
</tr>
<tr>
<td>6-25 μmol/l A23187</td>
<td>4-7</td>
<td>17-7</td>
</tr>
<tr>
<td>2 μg/ml collagen</td>
<td>3-7</td>
<td>9-9</td>
</tr>
<tr>
<td>6 μg/ml collagen</td>
<td>6-4</td>
<td>15-4</td>
</tr>
<tr>
<td>0-05 μg/ml PAF-acether</td>
<td>1-7</td>
<td>1-8</td>
</tr>
<tr>
<td>0-5 μg/ml PAF-acether</td>
<td>1-8</td>
<td>3-2</td>
</tr>
</tbody>
</table>

abnormal aggregation responses to ADP, arachidonate, low and high dose collagen, endoperoxide analogue, PAF-acether and A23187. This is suggestive of a defect in the prostaglandin pathway. We were able to exclude production of a biologically abnormal TXA₂ molecule, as has previously been described by showing that TXA₂-like material from our patient’s platelets produced normal aggregation of aspirin-treated normal platelets. In addition, platelet TXB₂ and malondialdehyde production were quantitatively normal. We also excluded the possibility that our patient’s platelets did not respond to endogenous TXA₂-like material due to a TXA₂/PGH₂ receptor abnormality as has been reported. That patient had normal aggregation and release to A23187. Similarly, A23187 induced aggregation is not inhibited by the TXA₂ receptor blocking compound AH 19437. It has been reported that high dose collagen and PAF-acether induce platelet aggregation and release independently of arachidonate metabolism and TXA₂ generation. Our patient’s platelets showed defective aggregation and release in response to collagen, PAF-acether and A23187. Furthermore, it is now accepted that A23187 induced aggregation is dependent on the mobilisation and response to intracellular platelet calcium. This would suggest a defect in either calcium content, mobilisation or utilisation of intracellular calcium. This concept is supported by the fact that platelet aggregation induced by A23187 was corrected by the addition of exogenous calcium to the washed platelets. This abnormality was not associated with any increase in the basal level of cyclic AMP which is believed to inhibit calcium mobilisation.

Therefore, we propose that our patient has a defect in a calcium dependent process, such as a calcium dependent protease or a calcium calmodulin binding defect which is overcome in washed platelets by the presence of extracellular calcium.

Table 2 Percentage release of platelet nucleotides after stimulation of PRP for 4 min in the aggregometer with the agonists. Each value is the mean of two determinations.

<table>
<thead>
<tr>
<th>Agonists (final concentration)</th>
<th>Patient</th>
<th>Control subject</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ATP</td>
<td>ADP</td>
</tr>
<tr>
<td>2-5 μmol/l A32187</td>
<td>3-2</td>
<td>5-9</td>
</tr>
<tr>
<td>6-25 μmol/l A23187</td>
<td>4-7</td>
<td>17-7</td>
</tr>
<tr>
<td>2 μg/ml collagen</td>
<td>3-7</td>
<td>9-9</td>
</tr>
<tr>
<td>6 μg/ml collagen</td>
<td>6-4</td>
<td>15-4</td>
</tr>
<tr>
<td>0-05 μg/ml PAF-acether</td>
<td>1-7</td>
<td>1-8</td>
</tr>
<tr>
<td>0-5 μg/ml PAF-acether</td>
<td>1-8</td>
<td>3-2</td>
</tr>
</tbody>
</table>

References

14 Summerfield GP, Keenan JP, Brodie NJ, Bellingham AJ.

Table 3 Platelet nucleotides levels of washed platelet suspension and the percentage nucleotide release following stimulation with A23187 in a calcium-free medium.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Control subject</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP</td>
<td>ADP</td>
</tr>
<tr>
<td>Total nucleotide levels (nmol/10⁶ platelets)</td>
<td>33-9</td>
</tr>
<tr>
<td>Percentage release to:</td>
<td>0-25 μmol/l A23187</td>
</tr>
</tbody>
</table>
The September 1983 issue

**Symposium report**

**Blood culture—current state and future prospects**
JC GOULD, BI DIERDEN

**Isolation of Legionella pneumophila from clinical specimens via amoebae, and the interaction of those and other isolates with amoebae**
TJ ROWBOTHAM

**Bacteriological examination of removed cerebrospinal fluid shunts**
R BAYSTON, TERESA SM LEUNG, BARBARA M WILKINS, BRENDI HODGES

**Evaluation of some methods for the laboratory identification of Haemophilus influenzae**
GM TEBBUTT

**Comparison of the continuous cell line 293 with human embryo kidney cells and human embryo fibroblast cells for the cultivation of ocular viruses**
DL YRRELL, APCH ROOME, JM DARVILLE, CR ASHLEY, J HARBOUR

**Correlation of lysosomal enzyme abnormalities in various forms of adult leukaemia**
GTN BESLEY, SE MOSS, AD BAIN, AE DEWAR

**Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids**
GP SUMMERFIELD, W TAYLOR, AJ BELLINGHAM, HJ GOLDSMITH

**Iron deficiency in sickle cell anaemia**
SALLY DAVIES, JOAN HENTHORN, MILICA BROZOVIC

**Zinc and copper concentrations in leucocytes and erythrocytes in healthy adults and the effect of oral contraceptives**
LESLEY J HINKS, BARBARA E CLAYTON, RS LLOYD

**Limitations of protein-coated charcoal in the separation of free from bound vitamin B12 in serum**
ELIZABETH JACOB, KIT-TAI J WONG

**Benefits of costing in the clinical laboratory**
PMG BROUGHTON, FP WOODFORD

**Fine needle aspiration biopsy of the thyroid gland: a study of 304 cases**
KC SUEN, NF QUENVILLE

**Immunological characterisation of plasminogen activators in the human vessel wall**
H LJUNGNER, L HOLMBERG, A KJELDGAARD, IM NILSSON, B Aasted

**Factor VIII as a marker of endothelial cells in follicular carcinoma of the thyroid**
HR HARACH, B JASANI, ED WILLIAMS

**A quantitative study of the size of benign and malignant lymphoid follicles**
J CROCKER, EL JONES, RC CURRAN

**Hepatocellular carcinoma complicating chronic granulomatous hepatitis**
WM MELIA, H CALVEY, B PORTMANN, R WILLIAMS

**Necrotising granulomata in prostatic resection specimens—a sequel to previous operation**
G LEE, N SHEPHERD

**Intramucosal carcinoma of the gastric antrum complicating Menetrier's disease**
GM WOOD, CHRISTINE BATES, RC BROWN, MS LOSOWSKY

**Recurrent insulinoma syndrome with metastatic glucagonoma**
PJS DUNN, MC SHEPPARD, DA HEATH, G SLANEY

**Technical method**
An electron microscopy method for studying full cross-sections of the human renal glomerulus
SR APARICIO, C WAKEFIELD

**Letters to the Editor**

**Notices**
Defective platelet aggregation to the calcium ionophore A23187 in a patient with a lifelong bleeding disorder.

S J Machin, J P Keenan and B A McVerry

*J Clin Pathol* 1983 36: 1140-1144
doi: 10.1136/jcp.36.10.1140

Updated information and services can be found at:
http://jcp.bmj.com/content/36/10/1140

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/